<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39396938</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>14</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Understanding the impact of pandemics on long-term medication adherence: directly observed therapy in a tuberculosis treatment cohort pre- and post-COVID-19 lockdowns.</ArticleTitle><Pagination><StartPage>1154</StartPage><MedlinePgn>1154</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1154</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-024-09994-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The COVID-19 pandemic negatively impacted tuberculosis (TB) treatment services, including directly observed therapy (DOT) programs used to promote medication adherence. We compared DOT adherence embedded in a research study before and after COVID-19 lockdowns in South Africa.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We analyzed data from 263 observational study participants undergoing drug susceptible (DS)-TB DOT between May 2017 to March 2022. Participants enrolled before October 2019 were considered 'pre-COVID-19' and those enrolled after September 2020 were considered 'post-COVID-19 lockdown groups. Negative binomial regression models were used to compare DOT non-adherence rates between the two lockdown groups. We then conducted a sensitivity analysis which only included participants enrolled in the immediate period following the first COVID-19 lockdown.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">DOT non-adherence rate was higher in the post-COVID-19 lockdown group (aIRR = 1.42, 95% CI = 1.04-1.96; p = 0.028) compared to pre-COVID-19 lockdown period, adjusting for age, sex, employment status, household hunger, depression risk, and smoked substance use. DOT non-adherence was highest immediately following the initial lockdown (aIRR = 1.74, 95% CI = 1.17-2.67; p = 0.006).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The COVID-19 lockdowns adversely effected adherence to TB DOT in the period after lockdowns were lifted. The change in DOT adherence persisted even after adjusting for socioeconomic and behavioral variables. We need a better understanding of what treatment adherence barriers were exacerbated by COVID-19 lockdowns to improve outcomes in post-pandemic times.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov Registration Number: NCT02840877. Registered on 19 July 2016.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Overbeck</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Section of Infectious Diseases, Department of Medicine, Boston Medical Center and Boston University Chobanian &amp; Avedisian School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malatesta</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carney</LastName><ForeName>Tara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Mental Health, Alcohol, Substance Use &amp; Tobacco Research Unit, South African Medical Research Council, Cape Town, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Mental Health, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>Bronwyn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Mental Health, Alcohol, Substance Use &amp; Tobacco Research Unit, South African Medical Research Council, Cape Town, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Mental Health, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Curtin enAble Institute, Faculty of Health Sciences, Curtin University, Perth, WA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parry</LastName><ForeName>Charles D H</ForeName><Initials>CDH</Initials><AffiliationInfo><Affiliation>Mental Health, Alcohol, Substance Use &amp; Tobacco Research Unit, South African Medical Research Council, Cape Town, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Stellenbosch University, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horsburgh</LastName><ForeName>Charles R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Section of Infectious Diseases, Department of Medicine, Boston Medical Center and Boston University Chobanian &amp; Avedisian School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Global Health, Epidemiology and Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Theron</LastName><ForeName>Danie</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Brewelskloof Hospital, Worcester, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Laura F</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warren</LastName><ForeName>Robin M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>South Africa Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Stellenbosch University, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Karen R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Section of Infectious Diseases, Department of Medicine, Boston Medical Center and Boston University Chobanian &amp; Avedisian School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouton</LastName><ForeName>Tara C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Section of Infectious Diseases, Department of Medicine, Boston Medical Center and Boston University Chobanian &amp; Avedisian School of Medicine, Boston, MA, USA. tcbouton@bu.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Infectious Diseases, Boston Medical Center Crosstown Center, 2nd floor 801 Massachusetts Ave, Boston, 02118, MA, USA. tcbouton@bu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02840877</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>K23 AI152930</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23AI152930</GrantID><Agency>National Institute of Allergy and Infectious Diseases</Agency><Country /></Grant><Grant><GrantID>R01AI119037</GrantID><Agency>National Institute of Allergy and Infectious Diseases</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000995">Antitubercular Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055118" MajorTopicYN="Y">Medication Adherence</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023801" MajorTopicYN="Y">Directly Observed Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013019" MajorTopicYN="N" Type="Geographic">South Africa</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014376" MajorTopicYN="Y">Tuberculosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000995" MajorTopicYN="Y">Antitubercular Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Mycobacterium tuberculosis</Keyword><Keyword MajorTopicYN="N">Adherence</Keyword><Keyword MajorTopicYN="N">Drug-susceptible TB</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">South Africa</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>13</Day><Hour>23</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39396938</ArticleId><ArticleId IdType="pmc">PMC11475609</ArticleId><ArticleId IdType="doi">10.1186/s12879-024-09994-7</ArticleId><ArticleId IdType="pii">10.1186/s12879-024-09994-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>John CA. Realizing the World Health Organization’s end TB strategy (2016–2035): how can social approaches to Tuberculosis elimination contribute to progress in Asia and the Pacific? Trop Med Infect Dis. 2019;4(1):28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6473717</ArticleId><ArticleId IdType="pubmed">30764510</ArticleId></ArticleIdList></Reference><Reference><Citation>Karim QA, Baxter C. COVID-19: impact on the HIV and tuberculosis response, service delivery, and research in South Africa. Curr HIV/AIDS Rep. 2022;19(1):46–53. 10.1007/s11904-021-00588-5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8783194</ArticleId><ArticleId IdType="pubmed">35064888</ArticleId></ArticleIdList></Reference><Reference><Citation>Government of South Africa Department of Health. 2020. https://www.gov.za/covid-19/about/about-alert-system. COVID-19: About Alert System.</Citation></Reference><Reference><Citation>Loveday M, Cox H, Evans D, Furin J, Ndjeka N, Osman M, et al. Opportunities from a new disease for an old threat: extending COVID-19 efforts to address tuberculosis in South Africa. South Afr Med J Suid-Afr Tydskr Vir Geneeskd. 2020;110(12):1160–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">33403958</ArticleId></ArticleIdList></Reference><Reference><Citation>Salari N, Hosseinian-Far A, Jalali R, Vaisi-Raygani A, Rasoulpoor S, Mohammadi M, et al. Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: a systematic review and meta-analysis. Glob Health. 2020;16(1):57. 10.1186/s12992-020-00589-w.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7338126</ArticleId><ArticleId IdType="pubmed">32631403</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahnavazi M, Rigi F, Heydarikhayat N. Treatment adherence and influencing factors in patients with tuberculosis during the COVID-19 pandemic: a mixed method study. Health Educ Health Promot. 2022;10(4):633–42 http://hehp.modares.ac.ir/article-5-60909-en.html.</Citation></Reference><Reference><Citation>Tola HH, Tol A, Shojaeizadeh D, Garmaroudi G. Tuberculosis treatment non-adherence and lost to follow up among TB patients with or without HIV in developing countries: a systematic review. Iran J Public Health. 2015;44(1):1–11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4449995</ArticleId><ArticleId IdType="pubmed">26060770</ArticleId></ArticleIdList></Reference><Reference><Citation>Satti SBR, Kondagunta N. Risk factors for DOTS treatment default among New HIV-TB Coinfected patients in Nalgonda (Dist.) Telangana (State): a Case Control Study. Indian J Community Med off Publ Indian Assoc Prev Soc Med. 2016;41(2):120–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4799634</ArticleId><ArticleId IdType="pubmed">27051086</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruru Y, Matasik M, Oktavian A, Senyorita R, Mirino Y, Tarigan LH, et al. Factors associated with non-adherence during tuberculosis treatment among patients treated with DOTS strategy in Jayapura, Papua Province, Indonesia. Glob Health Action. 2018;11(1):1510592. 10.1080/16549716.2018.1510592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6225439</ArticleId><ArticleId IdType="pubmed">30394200</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Yang Y, Qiao X, Wang L, Bai J, Yangchen T, et al. Factors influencing medication nonadherence to pulmonary tuberculosis treatment in Tibet, China: a qualitative study from the patient perspective. Patient Prefer Adherence. 2020;14:1149–58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7360411</ArticleId><ArticleId IdType="pubmed">32764888</ArticleId></ArticleIdList></Reference><Reference><Citation>Orooj M, Sharma B, Rabra S, Awasth S. Impact of COVID-19 pandemic on quality of life and medication adherence among pulmonary TB patients. Int J Curr Res Rev. 2021;13(6):119–24.</Citation></Reference><Reference><Citation>Otu AA. Is the directly observed therapy short course (DOTS) an effective strategy for tuberculosis control in a developing country? Asian Pac J Trop Dis. 2013;3(3):227–31.</Citation></Reference><Reference><Citation>Alipanah N, Jarlsberg L, Miller C, Linh NN, Falzon D, Jaramillo E, et al. Adherence interventions and outcomes of tuberculosis treatment: a systematic review and meta-analysis of trials and observational studies. PLOS Med. 2018;15(7):e1002595. 10.1371/journal.pmed.1002595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6029765</ArticleId><ArticleId IdType="pubmed">29969463</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers B, Bouton TC, Ragan EJ, White LF, McIlleron H, Theron D, et al. Impact of alcohol consumption on tuberculosis treatment outcomes: a prospective longitudinal cohort study protocol. BMC Infect Dis. 2018;18(1):488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6162918</ArticleId><ArticleId IdType="pubmed">30268101</ArticleId></ArticleIdList></Reference><Reference><Citation>Hann D, Winter K, Jacobsen P. Measurement of depressive symptoms in cancer patients: Evaluation of the center for epidemiological studies depression scale (Ces-d). J Psychosom Res. 1999;46(5):437–43. Available from: https://www.sciencedirect.com/science/article/pii/S0022399999000045.
</Citation><ArticleIdList><ArticleId IdType="pubmed">10404478</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard T, Coates J, Swindale A, Deitchler M. Household hunger scale: indicator definition and measurement guide. Wash DC Food Nutr Tech Assist II Proj FHI. 2011;360:23.</Citation></Reference><Reference><Citation>Babor T, Higgins-Biddle J, Saunders J, Monteiro M. The alcohol use disorders identification test, guidelines for use in primary care. Geneva: World Health Organization, Department of Mental Health and Substance Abuse Dependence; 2001. https://apps.who.int/iris/bitstream/handle/10665/67205/W?sequence=1. </Citation></Reference><Reference><Citation>Hahn JA, Murnane PM, Vittinghoff E, Muyindike WR, Emenyonu NI, Fatch R, et al. Factors associated with phosphatidylethanol (PEth) sensitivity for detecting unhealthy alcohol use: an individual patient data meta-analysis. Alcohol Clin Exp Res. 2021;45(6):1166–87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8254773</ArticleId><ArticleId IdType="pubmed">33837975</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha P, Lakshminarayanan SL, Cintron C, Narasimhan PB, Locks LM, Kulatilaka N, et al. Nutritional supplementation would be cost-effective for reducing tuberculosis incidence and mortality in India: the Ration optimization to impede tuberculosis (ROTI-TB) model. Clin Infect Dis off Publ Infect Dis Soc Am. 2022;75(4):577–85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9464065</ArticleId><ArticleId IdType="pubmed">34910141</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanna BA, Ebrahimzadeh A, Bruce EL, Morgan MA, Novak SM, Gerdes SR, et al. Multicenter evaluation of the BACTEC MGIT 960 system for recovery of mycobacteria. J Clin Microbiol. 1999;37(3):748–52. 10.1128/JCM.37.3.748-752.1999. Cited 2023 Jan 10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC84542</ArticleId><ArticleId IdType="pubmed">9986844</ArticleId></ArticleIdList></Reference><Reference><Citation>Diacon AH, van der Merwe L, Demers AM, von Groote-Bidlingmaier F, Venter A, Donald PR. Time to positivity in liquid culture predicts colony forming unit counts of Mycobacterium tuberculosis in sputum specimens. Tuberculosis. 2014;94(2):148–51 https://www.sciencedirect.com/science/article/pii/S1472979213002011.
</Citation><ArticleIdList><ArticleId IdType="pubmed">24456754</ArticleId></ArticleIdList></Reference><Reference><Citation>Melsew YA, Doan TN, Gambhir M, Cheng AC, McBryde E, Trauer JM. Risk factors for infectiousness of patients with tuberculosis: a systematic review and meta-analysis. Epidemiol Infect. 2018;146(3):345–53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9134570</ArticleId><ArticleId IdType="pubmed">29338805</ArticleId></ArticleIdList></Reference><Reference><Citation>Linh NN, Viney K, Gegia M, Falzon D, Glaziou P, Floyd K, et al. World Health Organization treatment outcome definitions for tuberculosis: 2021 update. Eur Respir J. 2021;58(2):2100804. Available from: http://erj.ersjournals.com/content/58/2/2100804.abstract.
</Citation><ArticleIdList><ArticleId IdType="pubmed">34413124</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragan EJ, Gill CJ, Banos M, Bouton TC, Rooney J, Horsburgh CR, et al. Directly observed therapy to measure adherence to tuberculosis medication in Observational Research: protocol for a prospective cohort study. JMIR Res Protoc. 2021;10(6):e24510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8277341</ArticleId><ArticleId IdType="pubmed">34132642</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathieu E, Ritchie H, Rodés-Guirao L, Appel C, Giattino C, Hasell J et al. Our world in data. 2020. Coronavirus Pandemic (COVID-19). https://ourworldindata.org/coronavirus.</Citation></Reference><Reference><Citation>Kabbur S, Patil B, Angolkar M, Narasannavar A. Effect of pandemic on DOTS treatment during COVID-19 lockdown- A cross-sectional study. Indian J Tuberc. 2023;70(3):324–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9463076</ArticleId><ArticleId IdType="pubmed">37562908</ArticleId></ArticleIdList></Reference><Reference><Citation>Chilot D, Woldeamanuel Y, Manyazewal T. Real-time impact of COVID-19 on clinical care and treatment of patients with tuberculosis: a ulticenter cross-sectional study in Addis Ababa, Ethiopia. Ann Glob Health. 2021;87(1):109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8603857</ArticleId><ArticleId IdType="pubmed">34824990</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanleeuw L, Zembe-Mkabile W, Atkins S. Falling through the cracks: increased vulnerability and limited social assistance for TB patients and their households during COVID-19 in Cape Town, South Africa. PLOS Glob Public Health. 2022;2(7): e0000708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10021457</ArticleId><ArticleId IdType="pubmed">36962428</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Gennaro F, Gualano G, Timelli L, Vittozzi P, Di Bari V, Libertone R, et al. Increase in Tuberculosis Diagnostic Delay during First Wave of the COVID-19 pandemic: data from an Italian infectious disease Referral Hospital. Antibiot Basel Switz. 2021;10(3):272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7998965</ArticleId><ArticleId IdType="pubmed">33800406</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, He W, Lei J, Liu G, Huang F, Zhao Y. Impact of COVID-19 pandemic on pre-treatment delays, detection, and clinical characteristics of tuberculosis patients in Ningxia Hui Autonomous Region, China. Front Public Health. 2021;9:644536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8175850</ArticleId><ArticleId IdType="pubmed">34095053</ArticleId></ArticleIdList></Reference><Reference><Citation>Aznar ML, Espinosa-Pereiro J, Saborit N, Jové N, Sánchez Martinez F, Pérez-Recio S, et al. Impact of the COVID-19 pandemic on tuberculosis management in Spain. Int J Infect Dis. 2021;108:300–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8078060</ArticleId><ArticleId IdType="pubmed">33930543</ArticleId></ArticleIdList></Reference><Reference><Citation>Dlangalala T, Musekiwa A, Brits A, Maluleke K, Jaya ZN, Kgarosi K, Mashamba-Thompson T. evidence of TB services at primary healthcare level during COVID-19: A scoping review. Diagnostics (Basel). 2021;11(12):2221. 10.3390/diagnostics11122221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8700083</ArticleId><ArticleId IdType="pubmed">34943458</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>